article thumbnail

CDMO Bionova branches into plasmid DNA to serve cell and gene therapy developers

Fierce Pharma

As Japanese chemical giant Asahi Kasei continues its foray into the biopharma contract manufacturing space, the company’s biologics CDMO is expanding its offerings to include starting materials for | Asahi’s U.S. As part of the pDNA pivot, Bionova is setting up a new facility in The Woodlands, Texas.

DNA 80
article thumbnail

Forge adds plasmid DNA manufacturing to integrate gene therapy production service

BioPharma Reporter

Forge Biologics has added plasmid DNA manufacturing to its roster of services, enabling it to vertically integrate its production process.

DNA 73
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Growing Demand for Oligonucleotides Proposes Shedload of Opportunities for Contract Manufacturers

Roots Analysis

These short, single-stranded DNA or RNA molecules have various applications in biopharmaceutical and biotechnology industries including, genetic testing, basic research, forensic analysis and other analytical procedures. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.

article thumbnail

Touchlight appoints Karen Fallen as CEO of Touchlight DNA Services

Drug Discovery Today

Former Lonza President of Biologics Manufacturing joins to continue rapid expansion of DNA contract manufacturing; Touchlight’s synthetic dbDNA in high demand as starting material in the manufacture of advanced therapies such as mRNA vaccines and cell and gene therapies

DNA 45
article thumbnail

Pfizer’s pill cuts COVID deaths and hospitalisations by 90%

pharmaphorum

There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.

DNA 116
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40
article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

Roots Analysis

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Nanoparticles Contract Manufacturing.